Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

NCT01261741 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

299

Enrollment

INDUSTRY

Sponsor class

Conditions

Memory Disorder
Retention Disorder, Cognitive
Subjective Cognitive Impairment
Memory, Concentration or Attention Problems

Interventions

DRUG: Memantine
DRUG: Placebo

Sponsor

Merz Pharmaceuticals GmbH